Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Bullish +55

Bristol Myers Squibb stock: Q3 sales beat lifts 2026 outlook

Earnings report Financial outlook Guidance raised AI-generated analysis

πŸ“ˆ Bristol Myers Squibb reported Q3 2026 revenue of USD 13.07 billion, a 7 percent year-over-year increase that beat analyst estimates.

πŸ’° Adjusted earnings per share reached USD 1.35, significantly surpassing the consensus estimate of USD 1.09.

πŸš€ The Growth Portfolio generated USD 7.7 billion in revenue, up 12 percent year over year, driven by key products like Opdivo Qvantig and Breyanzi.

πŸ’Š Eliquis revenue surged 25 percent to USD 4.69 billion within the Legacy Portfolio.

πŸ“ˆ The company raised its full-year 2026 sales guidance to a range of USD 49.75 billion to USD 50.25 billion.

⚠️ Adjusted earnings guidance was lowered to USD 6.35 to USD 6.55 per share due to acquired IPRD charges and licensing income.

πŸ“‰ Adjusted gross margin declined to 68.4 percent from 72.9 percent, primarily due to product mix changes and a one-time contract termination charge.

🏒 The stock traded at EUR 56.35 on Lang & Schwarz as of Friday, October 30, 2026.

Bullish Signals
  • Bristol Myers Squibb exceeded Q3 revenue expectations with USD 13.07 billion in sales, a 7 percent year-over-year increase.
  • Adjusted earnings per share of USD 1.35 significantly beat the analyst consensus estimate of USD 1.09.
  • The Growth Portfolio delivered strong performance with USD 7.7 billion in revenue, up 12 percent year over year.
  • Eliquis revenue grew robustly by 25 percent to reach USD 4.69 billion in the third quarter.
  • Management raised the full-year 2026 sales forecast to a range of USD 49.75 billion to USD 50.25 billion.
Risk Factors
  • Adjusted earnings guidance was lowered to USD 6.35 to USD 6.55 per share due to acquired in-process research and development charges.
  • Adjusted gross margin fell to 68.4 percent from 72.9 percent, impacting near-term profitability visibility.
  • A one-time charge linked to the termination of a contract contributed to the decline in adjusted gross margin.
Full Analysis
Bristol Myers Squibb reported third-quarter 2026 results that exceeded analyst expectations, driven by strong performance across its Growth and Legacy portfolios. The company posted revenue of USD 13.07 billion, a 7 percent year-over-year increase that surpassed the consensus estimate of USD 12.72 billion. Adjusted earnings per share reached USD 1.35, significantly beating the cited analyst estimate of USD 1.09. Key drivers included robust growth in the Growth Portfolio, which generated USD 7.7 billion in revenue, up 12 percent year over year. Specific products contributing to this expansion include Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos, and Opdualag. The Legacy Portfolio produced USD 5.4 billion, while Eliquis revenue rose notably by 25 percent to reach USD 4.69 billion. Looking ahead, Bristol Myers Squibb raised its full-year 2026 sales forecast to a range of USD 49.75 billion to USD 50.25 billion, up from the previous guidance of USD 49.0 billion to USD 50.0 billion. However, management lowered adjusted earnings guidance to USD 6.35 to USD 6.55 per share due to acquired in-process research and development charges and licensing income impacts. Financial metrics showed a decline in adjusted gross margin to 68.4 percent from 72.9 percent in the prior-year quarter, attributed to product mix changes and a one-time charge related to contract termination. Investors are weighing the strength of sales growth against these lower near-term earnings visibility factors as the company navigates deal-related charges.